SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-167467
Filing Date
2024-06-25
Accepted
2024-06-25 07:07:31
Documents
15
Period of Report
2024-06-25
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d857404d8k.htm   iXBRL 8-K 38298
2 EX-99.1 d857404dex991.htm EX-99.1 23202
6 GRAPHIC g857404g0625015152649.jpg GRAPHIC 3613
  Complete submission text file 0001193125-24-167467.txt   203525

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA howl-20240625.xsd EX-101.SCH 2517
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE howl-20240625_lab.xml EX-101.LAB 18699
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE howl-20240625_pre.xml EX-101.PRE 11688
18 EXTRACTED XBRL INSTANCE DOCUMENT d857404d8k_htm.xml XML 3862
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

IRS No.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 241066149
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)